117 results
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
of any of our contract manufacturers to maintain high manufacturing standards could result in injury or death of clinical trial participants or patients … demonstrated a direct anti-cancer effect by inducing apoptosis (cell death) and inhibiting proliferation in various cancer cell models (multiple myeloma, non
6-K
EX-99
BLRX
Bioline Rx Ltd
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
) is the most common type of pancreatic cancer and is expected to be the second leading cause of cancer-related death in the U.S. by 2023. Because
6-K
EX-99
BLRX
Bioline Rx Ltd
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
or until his or her earlier death, resignation, retirement or removal. Any additional directorships resulting from an increase in the number of directors
6-K
EX-99
BLRX
Bioline Rx Ltd
15 Sep 22
Current report (foreign)
8:39am
who may suffer damage to or loss of property or death or personal injury, whether arising directly or indirectly from the Insured Assets or their use
6-K
EX-1
kn5qq3iw1dnxf
4 Nov 21
BioLineRx Announces an Oral Presentation and Three
10:15am
6-K
EX-99
tw4qy b39b2q3c7f
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
424B5
x0iynf7ycri1c
21 Jan 21
Prospectus supplement for primary offering
4:31pm
424B5
ldkqishz65
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
9dp5 8tnj
31 Dec 20
Shelf registration (foreign)
4:37pm
424B5
mx5ial
31 Dec 20
Prospectus supplement for primary offering
4:31pm
6-K
EX-99
yjohucuwftwljrs11ba
16 Dec 20
Current report (foreign)
8:00am
424B5
aqsfkqk
13 Nov 20
Prospectus supplement for primary offering
4:31pm
424B5
ur4fej8 xicxhv
25 Sep 20
Prospectus supplement for primary offering
4:30pm
424B5
1uc513tr
3 Jun 20
Prospectus supplement for primary offering
8:33am
424B5
50jyx 5adqy
28 May 20
Prospectus supplement for primary offering
12:00pm